Navigation Links
Rejected Alzheimer's drug shows new potential
Date:7/31/2012

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of act
'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gay Adults Rejected by Parents Have Worse Health, Study Finds
2. Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
3. Weight Control Can Cut Womens Diabetes Risk, Study Shows
4. Mindfulness meditation reduces loneliness in older adults, Carnegie Mellon study shows
5. SEARCH study shows 1-year drop in HIV virus levels in rural Ugandan parish after campaign
6. Research shows potential of microneedles to target therapeutics to the back of the eye
7. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
8. Benefits of HIV drugs rise -- but less than previously believed, Penn study shows
9. Alzheimers Drug Shows Promise in Early Trial
10. Study shows colon and rectal tumors constitute a single type of cancer
11. Spouses of severe-sepsis patients at high risk of depression, U-M study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Cooking and ... 3.1 out of 5. This score reflects slightly positive ... of product specialization, low switching costs and a low ... by the low availability of substitutes for cooking and ... of steel and aluminum, key inputs in the production ...
(Date:12/26/2014)... “Many people become overwhelmed by the thought ... and phone calls with insurance companies,” The Jones Firm ... free eBook on pedestrian and bicycle accidents . ... bicycle auto accident claims assures the injured individual that ... handling their case while they focus on recovering. ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... ... Sidney Funk, a board certified OB-GYN with over 35 years experience, has joined the executive ... ... Funk, a board certified OB-GYN with over 35 years experience, has joined the executive team ...
... appears to effectively deliver genetic material into cells with minimal ... that this device, a vector, is able to deliver DNA ... be activated a critical step in gene therapy. This ... than other experimental materials, according to the research. Biomedical ...
... It is well-documented that when negotiating winding roads, drivers ... lane marking referred to as the tangent point. New ... in left-hand curves, wide curves and when leaving a curve, ... Alternatively, when drivers enter or maneuver through a ...
... used to prevent potentially dangerous blood clots in recovering ... acute medical illness, doctors have found in a multi-institutional ... and patients strictly confined to 24-hour bed rest, a ... reduced the chances of blood clots while only slightly ...
... Amanda Gardner HealthDay Reporter , TUESDAY, July 6 ... shorter telomeres may be at a higher risk of developing ... new research suggests. Telomeres are the "shoelace ends" that ... you age. Right now, the findings aren,t likely ...
... ... entire Diamond Dreams Collection. Full of Diamond Tennis Bracelets with the most exquisite design and ... ... completion of the entire Diamond Dreams Collection. Full of Diamond Tennis Bracelets with the most ...
Cached Medicine News:Health News:Jackson Surgical Assistants Names Dr. Sidney Funk as Medical Director 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Eye movements and sight distance reveal how drivers negotiate winding roads 2Health News:Extended use of anti-clotting drug helps some bedridden patients 2Health News:Extended use of anti-clotting drug helps some bedridden patients 3Health News:Shorter Telomere Length Again Linked to Cancer 2Health News:Shorter Telomere Length Again Linked to Cancer 3Health News:Jewelry Collection Announcement: Diamond Dreams Tennis Bracelet Collection 2Health News:Jewelry Collection Announcement: Diamond Dreams Tennis Bracelet Collection 3
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/24/2014)... 23, 2014 In response to urgent requests from the ... Sierra Leone , Direct Relief delivered two 10-bed ... the treatment of local health workers who contract Ebola while ... Ebola care center was constructed for foreign health care workers ... available for local Sierra Leonean health workers. With ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... effectiveness of Intercell,s Vaccine Enhancement (VE) Patch in combination ... in the U.S.- The study is fully funded by ... a 5 year USD 128 m contract with the ... and improve protection against an H5N1 pandemic influenza outbreak ...
... Immunotherapy Works Against Neuroblastoma-- PHILADELPHIA, May 28 A ... experimental therapy using elements of the body,s immune system ... challenging cancer of the nervous system.John M. Maris, M.D., ... co-authored the phase 3 clinical trial, which was led ...
Cached Medicine Technology:Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS 2Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS 3New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer 2New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer 3
... for the screening of factor-V-related APC resistance. ... test for the factor V:Q506 mutation is ... an excess of V-DEF Plasma bioreagent. The ... between heterozygous and homozygous factor V genotypes. ...
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
Medicine Products: